医学
肺动脉高压
围手术期
内科学
心脏病学
重症监护医学
人口
心脏外科
外科
环境卫生
作者
Sudarshan Rajagopal,Kurt Ruetzler,Kamrouz Ghadimi,Evelyn M. Horn,Marta Kelava,Kristina Kudelko,Ingrid Moreno‐Duarte,Ioana R. Preston,Leonie L. Rose Bovino,Nathaniel R. Smilowitz,Anjali Vaidya
出处
期刊:Circulation
[Ovid Technologies (Wolters Kluwer)]
日期:2023-03-16
卷期号:147 (17): 1317-1343
被引量:61
标识
DOI:10.1161/cir.0000000000001136
摘要
Pulmonary hypertension, defined as an elevation in blood pressure in the pulmonary arteries, is associated with an increased risk of death. The prevalence of pulmonary hypertension is increasing, with an aging population, a rising prevalence of heart and lung disease, and improved pulmonary hypertension survival with targeted therapies. Patients with pulmonary hypertension frequently require noncardiac surgery, although pulmonary hypertension is associated with excess perioperative morbidity and death. This scientific statement provides guidance on the evaluation and management of pulmonary hypertension in patients undergoing noncardiac surgery. We advocate for a multistep process focused on (1) classification of pulmonary hypertension group to define the underlying pathology; (2) preoperative risk assessment that will guide surgical decision-making; (3) pulmonary hypertension optimization before surgery to reduce perioperative risk; (4) intraoperative management of pulmonary hypertension to avoid right ventricular dysfunction and to maintain cardiac output; and (5) postoperative management of pulmonary hypertension to ensure recovery from surgery. Last, this scientific statement highlights the paucity of evidence to support perioperative pulmonary hypertension management and identifies areas of uncertainty and opportunities for future investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI